We have previously identified mouse DDA3 as a p53-inducible gene. To explore the functional role of DDA3, we screened a mouse brain cDNA library by the yeast two-hybrid assay, and identified the microtubule plus-end binding protein EB3 as a DDA3-interacting protein.
Introduction
Mutation of the p53 tumor suppressor is the most common genetic alteration in cancer; about half of the human cancers contain p53 mutation. In response to a variety of cellular stresses, p53 undergoes post-translational modifications and is stabilized and activated, which leads to growth arrest and apoptosis of cells; as a result, damaged cells are prevented from further replication (Vogelstein et al., 2000; Hofseth et al., 2004; Levine et al., 2004) . p53 is a sequence-specific transcription factor, the majority of p53 mutations in cancers are point mutations clustered within its DNAbinding domain that render the protein transcriptionally inactive (Hainaut et al., 1998) , indicating that transcriptional regulation is a major mechanism by which p53 implements its tumor suppressor function. In fact, it is well described that p53 targets are involved in apoptosis induction, cell-cycle inhibition and DNA repairing, thus contributing to the maintenance of genomic stability of cells. Notably, a number of studies have shown that p53 targets also include those that are implicated in promoting cell survival (Fang et al., 2001; Han et al., 2002; Ongusaha et al., 2003; Park and Nakamura, 2005) , presumably activation of the pro-survival pathway of p53 is necessary for cell cycle re-entering once the stress signals are subsided.
Activation of b-catenin oncogene is a common event in cancer. b-Catenin is a major downstream component of the Wnt signaling, which plays an important role in both early development and tumorigenesis (Behrens, 2000; Moon et al., 2004) . Activation of Wnt signaling inactivates glycogen synthase kinase 3b (GSK-3b), a member of the multicomponent b-catenin degradation complex that also includes adenomatous polyposis coli (APC) and axin/conductin, and leads to inappropriate b-catenin accumulation. Both APC and b-catenin are substrates of GSK-3b; complex formation facilitates the phosphorylation and degradation of b-catenin. Stabilization of b-catenin by Wnt signaling results in its cytosolic accumulation and nuclear translocation where it interacts with T-cell factor (TCF)/lymphoid enhancer factor (LEF) and activates many growth-stimulatory genes such as cyclin D1 and c-myc (He et al., 1998; Tetsu and McCormick, 1999) . APC is a multifunctional protein located at microtubule plus-ends and interacts with many binding partners (Bienz, 2002; Hanson and Miller, 2005; Senda et al., 2005) , including the microtubule plusend protein EB1, which binds to the C-terminus of APC (Su et al., 1995; Honnappa et al., 2005) . The importance of this interaction in carcinogenesis is shown by the finding that mutation of the APC tumor suppressor that disrupts its interaction with EB1 occurs commonly in the familial and sporadic colon cancers (Su et al., 1995) . A recent finding has indicated that EB1 is overexpressed in many human esophageal squamous cell carcinoma (ESCC), and may play a role in the development of ESCC by affecting APC function and activating the b-catenin/TCF pathway (Wang et al., 2005) . Recently, an APC homolog APC2 has been identified and shown to be predominantly expressed in the central nervous system (Nakagawa et al., 1998; van Es et al., 1999) . APC2 bears significant sequence homology to APC, except in the C-terminal region, where the two proteins share little similarity. Similar to APC, APC2 binds microtubule and antagonizes Wnt signaling by depleting cytoplasmic b-catenin (Nakagawa et al., 1998; van Es et al., 1999) . It has been shown that allelic imbalance on APC2 gene locus is common in sporadic ovarian tumors (Jarrett et al., 2001) , suggesting that APC2 is a potential tumor suppressor gene. APC2 binds to EB3, a brain specific EB1 homolog identified previously as a microtubule-associated protein Su 2001, Nakagawa et al., 2000) . The biological significance of the APC2-EB3 interaction remains to be elucidated.
We have identified previously the mouse DDA3 as a p53 direct target gene whose function has yet to be clarified (Lo et al., 1999; Hsieh et al., 2002) . DDA3 encodes a protein rich in serine and proline, and contains a coiledcoil region plus six putative SH3-domain-binding motifs PXXP. It therefore may provide a point of interaction for p53 with other signaling pathways and contribute to the complexity and specificity of p53 signaling networks. Miller et al. (2006) have recently shown by microarray analysis that DDA3 is frequently upregulated in human malignant peripheral nerve sheath tumor cells. We here report that DDA3 is a novel microtubule-binding and bundling protein that interacts directly with EB3 and APC2. In contrast to APC2, expression of DDA3 and EB3 increases the b-catenin-mediated transcription and cyclin D1 expression. In congruous with this finding, knockdown of DDA3 or EB3 inhibits b-catenin-dependent transcription and the ability of cells to form colonies. Our findings that DDA3 physically and functionally interacts with microtubules and the associated proteins EB3 and APC2 and enhances the b-catenin-dependent gene expression provide a basis for functionally connecting p53 to the b-catenin pathway, and may implicate p53 in the microtubule-dependent activities.
Results

Identification of EB3 as a DDA3-binding protein by yeast two-hybrid screening
To explore the functional roles of DDA3, we identified its interacting partners by the LexA-based yeast two-hybrid system. Because mouse DDA3 is predominantly expressed in the brain (Lo et al., 1999) , we screened a mouse brain cDNA library using the coding region of DDA3 fused to the 3 0 -end of LexA as the bait. Among the interacting candidate genes was a clone containing the 3 0 -end sequence of the mouse EB3 gene. The full-length mouse EB3 cDNA was cloned (NCBI accession no. AF468005); sequence comparison revealed that it encodes a protein of 281 amino acids that shares 54 and 99% identity to the human EB1 and EB3, respectively, and differs from its human counterpart in only two amino acids (A198T and L210V). Similar to other EB family proteins, EB3 has a highly conserved Nterminal region containing the calponin homology (CH) domain (residues 14-116) and a C-terminal region (residues 217-265) unique to EB family members (Bu and Su 2003) . Northern blot analysis demonstrated that mouse EB3, like DDA3, was predominantly expressed in the brain (data not shown). Yeast two-hybrid assay further verified that DDA3 interacted with the fulllength EB3, but not EB1, indicating specificity of the interaction (data not shown).
DDA3 binds EB3 in vitro and in vivo
To confirm the interaction of DDA3 and EB3, we tested the in vitro binding of the two proteins by the glutathione S-transferase (GST) pull-down assay. The in vitro-translated and 35 S-labeled EB3 was incubated with GST-DDA3 fusion protein immobilized on glutathione-Sepharose beads, and the mixture was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). As indicated in Figure 1a (left), EB3 bound to GST-DDA3, but not control GST. Likewise, the in vitro-translated DDA3 could also be pulled down by GST-EB3 (Figure 1a , right). The physical interaction of DDA3 and EB3 in cells was examined by co-immunoprecipitation. The FLAGtagged DDA3 and HA-tagged EB3 were co-expressed in MCF7 cells, total cell lysates were prepared and DDA3 was precipitated with anti-FLAG antibody. The immunoprecipitated proteins were separated by SDS-PAGE and analysed for the presence of EB3 by immunoblotting with anti-HA antibody. As shown in Figure 1b , anti-FLAG antibody co-precipitated HA-EB3. Reciprocal co-immunoprecipitation with anti-HA antibody for EB3 precipitation also pulled down FLAG-tagged DDA3 (Figure 1c) . These results clearly demonstrated that DDA3 and EB3 form complex in cells.
The subcellular colocalization of DDA3 and EB3 was analysed by immunofluorescence. HeLa cells transfected with CMV-DDA3 and FLAG-EB3 were fixed and reacted with polyclonal anti-DDA3 and anti-FLAG antibody, followed by rhodamine-conjugated donkey anti-rabbit immunoglobulin G (IgG) and fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG, respectively. As shown by confocal microscopy analysis (Figure 1d ), DDA3 and EB3 were found to colocalize in the cytoplasm and manifested as dense circular filaments around the nucleus.
Binding of DDA3 and EB3 in cells requires intact microtubules Because EB3 is a microtubule-associated protein (Nakagawa et al., 2000; Bu and Su 2001) , we tested whether the binding of DDA3 and EB3 in cells required microtubules. MCF7 cells transfected with HA-EB3 and FLAG-DDA3 were treated with microtubule-disrupting agent nocodazole before immunoprecipitation, under such circumstances, EB3 was not detectable in the DDA3 immunoprecipitates (Figure 2a Determination of mutual interacting regions of DDA3 and EB3 GST pull-down assays were conducted to define the domains of DDA3 responsible for binding to EB3. Deletion plasmids containing various regions of DDA3 fused to the 3 0 -end of GST were constructed (primers for generating each cDNA fragment are summarized in Supplementary Table 1 ). Roughly equal amounts of the GST-fusion fragments of DDA3 were immobilized on glutathione-Sepharose beads and mixed with the in vitro-translated 35 S-labeled EB3. As shown in Figure 3a and summarized in Figure 3b , fragments of DDA3 containing residues 118-241, including aa 1-241, 55-241 and 118-241, were capable of binding to EB3, notably those containing the C-terminal 242-329 residues of DDA3 (aa 55-329, 118-329 and 242-329) exhibited the strongest affinity for EB3. In contrast, the N-terminal regions of DDA3 (aa 1-54, 1-117 and 55-117) were unable to bind EB3. Reciprocal experiments to determine the DDA3 binding domains of EB3 showed that they were distributed to the N-and C-terminal regions of EB3. As indicated, fragments containing aa 14-116 (the CH domain) and aa 195-281 interacted equally effective with DDA3 as the full-length EB3 (Figure 3c and summarized in 3d).
DDA3 is a microtubule-binding protein
The ability of DDA3 to bind EB3 and the pattern of its subcellular distribution (Figure 1d ) suggested that DDA3 could itself be a microtubule-associated protein. This possibility was examined by immunofluorescence using specific antibodies for DDA3 and a-tubulin in HeLa cells ectopically expressing DDA3. As shown, DDA3 colocalized with tubulin in the cytoplasm in a filamentous-like pattern (Figure 4a ). It was found localized to the mitotic spindle in prometaphase, and to the midbody where microtubules bundled in cells undergoing cytokinesis, suggesting close association of DDA3 with microtubules throughout cell cycle progression.
We were unable to detect endogenous DDA3 by immunofluorescence in a number of cell lines surveyed. Because DDA3 is predominantly expressed in the brain, we employed cultured mouse dopaminergic (DM) primary cells to verify its microtubule localization. As shown, endogenous DDA3 ( Figure 4b ) and EB3 (Figure 4c , top) were found to colocalize with tubulin at the midbody in DM cells undergoing cytokinesis. Similar to its human counterpart (Bu and Su, 2001 ), endogenous mouse EB3 was located mainly to the tips of microtubules where it appeared as a short cometlike distribution (Figure 4c , bottom). The finding that ectopically transfected EB3 decorated the entire S-labeled EB3, and the mixture was separated by SDS-PAGE. Bound EB3 was revealed by autoradiography (left). Reciprocal experiment using GST-tagged EB3 was shown to pull down the in vitro translated DDA3 (right). GST was included as a negative control. (b), (c) Interaction of DDA3 with EB3 in vivo. MCF7 cells grown in a 10-cm dish were co-transfected with 10 mg each of HA-EB3 and FLAG-DDA3 by LipofectAMINE. Lysates were prepared after 24 h and immunoprecipitated (IP) with antibodies against HA (20 mg, BAbco) or FLAG (20 mg, Sigma) as shown. The immunoprecipitates were resolved by SDS-PAGE, and immunoblotted (IB) with the indicated antibodies. Cell lysates containing 50 mg total soluble proteins were used as a positive control (input). Immunoprecipitation with normal mouse IgG was used as the negative control. (d) Colocalization of DDA3 and EB3 in cells. HeLa cells cultured on coverslips were co-transfected with CMV-DDA3 and FLAG-EB3 by calcium phosphate-based transfection. Twenty-four hours later, cells were fixed, reacted with antibodies against DDA3 (polyclonal, 1:2000 dilution) and FLAG (Sigma, 1:500 dilution), followed by rhodamine-conjugated donkey antirabbit IgG and FITC-conjugated goat anti-mouse IgG staining, respectively and visualized by a confocal microscope.
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Identification of microtubule-interacting/bundling domains of DDA3 and EB3
We next determined the domains of DDA3 responsible for microtubule interaction by immunofluorescence analysis. A series of enhanced green fluorescent protein (EGFP)-tagged DDA3 deletion plasmids were constructed and transfected into DM cells, and analysed by immunofluorescence using a specific antibody against a-tubulin. The results are shown in Supplementary Figure 1 and summarized in Figure 5a . As indicated, truncated mutants carrying the central (aa 118-241) and the C-terminal (aa 242-329) regions of DDA3 were both able to target microtubules. In contrast, the N-terminal fragments (aa 1-54 and 1-117) of DDA3 were unable to interact with microtubules. Analysis of the microtubule-interacting domain of DDA3 (aa 118-329) did not reveal any sequence homology with the presently known microtubule-binding motifs. We have noticed that expression of DDA3 and its microtubule-interacting mutants could promote the formation of microtubule bundles (Supplementary Figure 1 ), suggesting a microtubule-stabilizing role for DDA3. Similar approaches to map the microtubule-interacting domain of EB3 revealed it to reside in the N-terminal 165 amino acids harboring the CH domain (Supplementary Figure 2 and summarized in Figure 5b ).
Direct binding of DDA3 and EB3 to the microtubules
We investigated whether DDA3 could bind microtubules directly by conducting the in vitro microtubuleco-sedimentation assay. In this assay, purified GST-fusion DDA3 protein was mixed with prepolymerized microtubules. After separation by ultracentrifugation, microtubule-interacting protein would cosediment with microtubules in the pellet and could be detected by immunoblotting using a GST-antibody. As indicated in Figure 6a , full-length DDA3 showed up in the pellets in the presence of microtubules, indicating association of DDA3 with microtubules is through direct binding. Consistent with mapping by immunofluorescence (Figure 5a ), the C-terminal fragments (aa 242-329 and 118-329), but not aa 1-54, bound to microtubules. Specificity of the assay was performed by mixing bovine serum albumin (BSA) or MAP2 with the microtubules, as expected, MAP2, but not BSA, cosedimented with microtubules in the pellet (Figure 6a , right). As shown in Figure 6b , EB3 binds directly to the microtubules with its N-terminal CH domain (aa 1-165).
Because the microtubule-binding domain of DDA3 (aa 118-241, 242-329) overlapped with its EB3 interacting region, co-sedimentation assay was performed to examine whether the presence of DDA3 or EB3 would affect each other's binding to the microtubules. Dosedependent assays were performed and showed that the saturating amounts of DDA3 and EB3 under the microtubule concentration used were approximately 6 mg for each protein (Figure 6c ). The binding of DDA3 or EB3 in the presence of excess amounts of the other protein was then examined to address whether they would compete with each other for microtubule binding. As indicated in Figure 6d , the microtubulebound DDA3 increased significantly by the simultaneous addition of saturating amounts of EB3 (top, compare lanes 1 with 2 and 4 with 5). Similarly, the presence of DDA3 could also enhance the binding of EB3 to the microtubules (middle, compare lanes 2-3 and 5-6).
To test the functional interaction of DDA3 and EB3 with microtubules, we examined their effects on microtubule polymerization using a fluorescence-based assay kit from Cytoskeleton (Denver, USA). The GST-DDA3 and GST-EB3 were separately incubated with purified tubulins, polymerization was followed by fluorescence enhancement owing to the incorporation of fluorescent reporters into microtubules. As indicated in Figure 6e , full-length DDA3 only slightly enhanced fluorescence DDA3 interacts with EB3 and activates b-catenin signaling P-C Hsieh et al emission; however, the C-terminal microtubule-binding fragment (aa 242-329) substantially promoted microtubule polymerization. Similar to EB1, which alone did not influence microtubule polymerization (Nakamura et al., 2001) , we found that EB3 had no detectable effect on microtubule polymerization. As a control, a robust increase in tubulin polymerization was seen by the addition of taxol.
DDA3 and EB3 activate b-catenin-dependent gene expression Expression of APC2, the EB3-binding partner, has previously been shown to inhibit the b-catenin-mediated transcription (Nakagawa et al., 1998) , we investigated whether EB3 and DDA3 could affect b-catenin signaling. Cells were cotransfected with a luciferase reporter construct specific for b-catenin/TCF (pTOP-FLASH) plus increasing amounts of expression plasmids for DDA3 and EB3, and luciferase activity was determined. As shown in Figure 7a (top), expression of DDA3 and EB3 resulted in increased luciferase activity in a dosedependent manner. Specificity of the TCF reporter was confirmed by pFOP-FLASH luciferase construct containing mutated TCF sites. As expected, transcription from this reporter plasmid was not affected by either DDA3 or EB3 (data not shown). In agreement with this DDA3 interacts with EB3 and activates b-catenin signaling P-C Hsieh et al result, we observed increased protein levels of b-catenin in cells expressing DDA3 and EB3 (Figure 7a, bottom) . The possibility that expression of DDA3 and EB3 would lead to increased transcription of cyclin D1, a bcatenin target, was examined. As indicated in Figure 7b (top), both DDA3 and EB3 upregulated cyclin D1 promoter-mediated luciferase activity in a dose-dependent manner. In accordance with the modest induction of luciferase activity, we noted an increase in cyclin D1 protein levels in cells expressing either DDA3 or EB3, as compared with vector alone control (Figure 7b,  bottom) .
To address the effects of endogenous DDA3 and EB3 on b-catenin signaling, we established stable clones by separately inhibiting DDA3 and EB3 expression with specific siRNAs in N2a mouse neuroblastoma cells. As shown in Figure 7c (left), siRNA effectively lowered the expression of the ectopically transfected EGFP fusion constructs of DDA3 and EB3. Consistent with results from overexpression of EB3 and DDA3 (Figure 7a ), blocking the expression of endogenous EB3 (pS-EB3) and DDA3 (pS-DDA3 clones 1 and 2) significantly suppressed the b-catenin-mediated luciferase activity (Figure 7c, right) .
The observation that transfection of DDA3 alone enhanced the b-catenin-mediated transcription prompted us to explore whether DDA3 bound directly to APC2. Two N-terminal truncated fragments of APC2, aa 700-2275 containing b-catenin and EB family binding regions and aa 1577-2275 harboring EB family binding domain, were in vitro translated and 35 S-labeled to be tested for binding to GST-DDA3; binding to GST-EB3 was performed as a positive control. As shown in Figure 7d (top), DDA3 and EB3 were both able to interact directly with the truncated fragments of APC2. In contrast, neither DDA3 nor EB3 bound directly to b-catenin (Figure 7d, bottom) .
Knockdown of EB3 or DDA3 suppresses colony formation in tumor cells
Elevated b-catenin activity has been linked to increased proliferation and colony-forming ability of cells. Effects of endogenous DDA3 and EB3 on cell growth were examined by colony formation assay using N2a neuroblastoma cells and TM4 sertoli cells. Cells were cotransfected with pSUPER (pS), pS-DDA3 or pS-EB3 and pRc-CMV carrying the neo-resistant gene. The drug-resistant colonies were scored at day 14 after G418 selection. As shown in Figure 7e , suppression of DDA3 or EB3 expression significantly inhibited colony formation in both tumor cell lines. To determine why cells Figure 2) for 24 h, localization of the fragments to microtubules was revealed by immunostaining as described in Figure 4 . Plus and minus signs indicate proteins that do and do not bind, respectively, to bundle microtubules. Numbers are amino acid (aa) residues for DDA3 (a) and EB3 (b). MT, microtubule; NLS, nuclear localization signal. The microtubule-interacting domains are mapped to aa 118-241 and 242-329 for DDA3 and aa 1-165 for EB3.
DDA3 interacts with EB3 and activates b-catenin signaling P-C Hsieh et al lacking EB3 and DDA3 have reduced colony formation, cells were co-transfected with an EGFP expression plasmid together with pSUPER-EB3, pSUPER-DDA3 or pSUPER. After 48 h, the cells were pulse-labeled with BrdU for 2 h and reacted with an anti-BrdU antibody.
As indicated in Figure 7f , BrdU incorporation was significantly suppressed in cells depleted of either EB3 or DDA3. On the contrary, we could not detect any increment in the subG1 DNA content when analysed by flow cytometry for cell cycle distribution (data not shown), suggesting that the suppression of colony formation is due to cell cycle arrest but not apoptosis. were mixed in the presence ( þ ) or absence (À) of purified and pre-polymerized microtubules (9 mg). Recovery of GST-tagged proteins in the pellet fraction containing polymerized microtubules was determined by immunoblotting using anti-GST antibodies (MBL, 1:1000 dilution). MAP2 (2 mg) and BSA (2 mg) were also included as a positive and negative control, respectively, for the assay. Recovery of these proteins in the pellet fraction was determined by Coomassie Blue staining (Figure 6a, right) . (c) Dose-dependent binding of DDA3 and EB3 to microtubules. Increasing amounts of purified GST-DDA3 (top) or GST-EB3 (bottom) as indicated were mixed in the presence ( þ ) or absence (À) of pre-polymerized microtubules (9 mg). Microtubule-bound proteins were detected as described in (a). (d) DDA3 and EB3 complement each other for microtubule binding. Microtubule-sedimentation assays were performed as described above in the presence of saturated amounts of purified GST-DDA3 and GST-EB3 as indicated, alone or in combination, to the pre-polymerized microtubules. Bound proteins were detected by immunoblotting with GST antibodies (MBL, 1:1000 dilution) after resolving by SDS-PAGE. As shown, the presence of EB3 enhanced the binding of DDA3 to the microtubules, and vice versa. (e) Effects of DDA3 and EB3 on microtubule polymerization. Equimolar concentrations of GST-DDA3 or GST-EB3 were incubated with purified tubulin, polymerization was monitored by the increase in fluorescence over a period of 72 min. Excitation was at 360 nm and emission at 420 nm. Taxol (3 mM) was used as a positive control.
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Discussion
Much evidence indicates that the transcriptional activity of p53 is critical to its function as a tumor suppressor.
To explore the biological significance of DDA3, a previously identified p53 direct transcriptional target, we searched for DDA3 interacting partners by the yeast two-hybrid screening. We here report the identification of the microtubule end-binding protein EB3 as a DDA3 interacting protein. Binding of DDA3 and EB3 is demonstrated in vitro by GST pull-down assay and in cells ectopically expressing DDA3 and EB3 by coimmunoprecipitation and subcellular colocalization. We further show that DDA3 binds directly to the EB3 interacting partner APC2. Although DDA3 binds to EB3 in vitro in the absence of microtubules, interaction of these two proteins in cells requires intact microtubules, as shown by the immunoprecipitation analysis that the binding is disrupted by nocodazole, but not by taxol. One likely explanation for this discrepancy is that much higher concentrations of proteins were used for in vitro GST pull-down assay, as compared with those inside cells. It is tempting to speculate that microtubules may serve as a scaffold for bringing two microtubule-associated proteins, DDA3 and EB3, to the close proximity of the cytoskeleton, thus increasing their local concentrations and enhancing the chances of their mutual interaction. In addition, microtubules could provide an environment for stabilizing the complex formation between EB3 and DDA3. This is supported by the in vitro binding assay indicating that the simultaneous presence of EB3 and DDA3 can promote each other's binding to the microtubules. Finally, amino-acid sequence analysis reveals the presence of multiple consensus kinase phosphorylation sites on DDA3. We have found that DDA3 was phosphorylated in cells treated with nocodazole (data not shown), whether phosphorylation affects its interaction with EB3 remains to be elucidated.
We have presented several lines of evidence showing that DDA3 is a novel microtubule-binding and bundling protein. The localization of ectopically expressed DDA3 to the microtubules was observed throughout the cell cycle, despite dynamic changes microtubules undergo during mitotic progression. This interaction does not depend on the presence of EB3, our results indicate that DDA3 is localized to the microtubules in the EB3-depleted N2a cells (data not shown). In addition, endogenous DDA3 was located to the midbody where microtubule is stabilized and bundled. Using the in vitro microtubule spin-down assay, we showed that DDA3 bound directly to the microtubules with its C-terminal portion, which was further confirmed by immunofluorescence analysis in vivo. We have found that ectopic DDA3 expression prompted microtubules to form bundles, which remained stable in the presence of nocodazole (data not shown), suggesting that DDA3 may affect the stability of microtubules. Although the full-length DDA3 only caused a very slight increase in fluorescence in the in vitro microtubule-polymerization assay, it is noteworthy that the C-terminal microtubulebinding fragment of DDA3 (aa 242-329) substantially enhanced the rate of polymerization. It is possible that the C-terminal region might be normally inaccessible for and cyclin D1 promoter-mediated (b, top) luciferase activity. H1299 cells cultured in a 12-well plate were co-transfected with 0.5 mg each of pTOP-FLASH-Luc or cyclin D1-promoter-Luc and CMV-LacZ (0.3 mg/per well) along with increasing amounts of plasmids expressing DDA3 and EB3 as indicated. Luciferase activity was determined at 24 h after transfection and normalized with b-galactosidase activity. Results were expressed as fold of induction relative to the vector alone control from three independent experiments. Bars, s.d.; *Po0.05. Extracts of H1299 cells transfected with CMV-DDA3 and CMV-EB3 for 24 h were analysed for protein levels of b-catenin (a, bottom) and cyclin D1 (b, bottom) by immunoblotting. Expression of tubulin was included as an internal control. (c) Knockdown of DDA3 and EB3 expression suppressed pTOP-FLASH luciferase activity. N2a cells were transfected with pSUPER-DDA3 (pS-DDA3) and pSUPER-EB3 (pS-EB3) designed to target DDA3 and EB3; transfection of pSUPER (pS) was included as a control. Cells were selected in culture medium containing 0.5 mg/ml G418 for 14 days, and the G418-resistant colonies were cloned. Two DDA3 knockdown clones, 1 and 2, were selected for further analysis. The knockdown clones were transfected with EGFP-fusion constructs of DDA3 (top) and EB3 (bottom), lysates were prepared and analysed by Western blotting using DDA3 and EB3 antibodies. As shown (c, left), expressions of DDA3 and EB3 were effectively suppressed. The EB3 and DDA3 knockdown clones (pS-EB3 and pS-DDA3 clones 1 and 2) and pS control cells (cultured in 12-well plates) were co-transfected with plasmids expressing pTOP-FLASH-Luc (0.3 mg/per well) and pRL-TK expressing rellina luciferase (0.1 mg/per well), lysates were prepared after 24 h for luciferase activity (c, right). Activities were corrected for transfection efficiency by normalizing with rellina luciferase activity, and are expressed as fold of induction relative to the vector alone control. Results shown are the mean values from three independent experiments; bars, s.d.; *Po0.05. (d) DDA3 binds to APC2, but not b-catenin. The GST pull-down assays were performed with GST-DDA3 and the APC2 in vitro translated (IVT) N-terminal truncated fragments encompassing aa 700-2275 and aa 1577-2275, and the bound proteins were revealed by autoradiography (top). GST protein was included as a negative control, and GST-EB3 as a positive control. For analysing the possible interaction with b-catenin, EB3 (lower left) and DDA3 (lower right) were in vitro translated and 35 S-labeled and incubated with the GST-tagged b-catenin immobilized on glutathione-Sepharose beads. (e) Knockdown of EB3 and DDA3 inhibits colony formation in tumor cells. The N2a or TM4 cells were plated at a density of 10 4 cells in a 6-cm plate and cotransfected with 5 mg each of pSUPER-EB3 (pS-EB3), pSUPER-DDA3 (pS-DDA3) or control vector pSUPER (pS) together with pRc-CMV (0.5 mg), cells were cultured in the presence of G418 (500 mg/ml for N2a and 600 mg/ml for TM4). The G418-resistant colonies were scored at day 14 after fixing and staining with crystal violet (1 mg/ml). Representative plates from colony formation assays are shown. Numbers represent average percentages of colonies relative to that of the pS vector control from three independent experiments. (f) Knockdown of EB3 and DDA3 inhibits DNA synthesis. N2a cells cultured on coverslips in a six-well plate were cotransfected with 0.1 mg EGFP expression plasmid together with 1 mg each of pSUPER-EB3, pSUPER-DDA3 or pSUPER. After 48 h, the cells were pulse-labeled with BrdU for 2 h, fixed and stained with an anti-BrdU monoclonal antibody followed by rhodamine-conjugated antimouse IgG. Nuclei were counterstained with the non-specific DNA-intercalating dye DAPI. At least 500 EGFP-positive cells were analysed for each sample.
DDA3 interacts with EB3 and activates b-catenin signaling P-C Hsieh et al enhancing microtubule polymerization. However, being a serine-rich protein, there could be situations where DDA3 may undergo phosphorylation-induced conformational switches, making the C-terminal region available for binding and promoting microtubule assembly. In this sense, our findings suggest that the ability of DDA3 to stimulate microtubule polymerization is a regulated process. Microtubules are key components of the cytoskeleton responsive to many incoming signals by changing the structural scaffolds during cell migration and cell cycle progression. Dynamic assembly of the microtubules is highly regulated both spatially and temporally by the microtubule-associated proteins, and is crucial for many cellular activities. Besides DDA3, p53 modulates the expression of several microtubuleassociated proteins, including survivin (Hoffman et al., 2002) and stathmin (Johnsen et al., 2000) , suggesting that p53 may play some roles in the microtubulemediated functions. We found that DDA3 and EB3 interacted directly with APC2, however, in contrast to APC2 which inhibits b-catenin signaling (Nakagawa et al., 1998; van Es et al., 1999) , expression of either DDA3 or EB3 resulted in increased b-catenin-mediated transcription and accumulation of protein levels of b-catenin and cyclin D1. Furthermore, knockdown of EB3 or DDA3 expression inhibited b-catenin-mediated transactivation and suppressed colony forming ability and DNA synthesis in tumor cells. Our results are consistent with a model (Figure 8 ) which by interacting with APC2, EB3 and DDA3 may affect the dynamic formation of APC2/ b-catenin destruction complex, resulting in the accumulation of b-catenin and stimulation of b-catenindependent pathways, including increased transcription of cyclin D1 which may lead to growth promotion. In agreement with this finding, DDA3 has recently been identified by microarray analysis as a gene frequently upregulated in human malignant peripheral nerve sheath tumor cells (Miller et al., 2006) . p53 has previously been linked to APC in regulating b-catenin degradation through transcriptional activation of its target Siah, a component of the APC complex that regulates b-catenin proteolysis in a GSK-3b independent manner (Matsuzawa and Reed 2001) . In clear contrast to DDA3, which activates b-cateninmediated transcription, Siah downregulates b-catenin and sensitizes cells to apoptotic death in response to DNA damage (Iwai et al., 2004) . The distinct outcome of these two p53 targets on b-catenin signaling may be explained by the multifaceted roles of p53 in stress response; this is in part revealed by the complex array of genes regulated by p53 activation. In addition to the better characterized genes related to apoptosis and growth arrest, p53 also coordinates the expression of genes for cells to compensate or feedback regulate stresses and genes that are required to recover from DNA damage. This latter group of survival genes encode for proteins that are involved in promoting cell survival and preventing apoptosis. For example, the heparin-binding EGF-like growth factor (HB-EGF) (Fang et al., 2001 ) is a p53 direct target that contributes to the p53-mediated activation of mitogen-activated protein kinase and Akt, and is shown to prevent the H 2 O 2 -induced apoptosis. Moreover, the recently identified p53-inducible gene TIGAR (Bensaad et al., 2006 ) is shown to inhibit reactive oxygen species (ROS) production and protect cells from ROS-associated apoptosis. The identification of DDA3 as a p53 target that increases b-catenin-mediated transcription and promotes colony formation expands the subset of genes involved in the pro-survival aspect of p53 action and provides an alternative functional linkage of p53 to the b-catenin signaling pathway.
Materials and methods
Cell culture and transfection
The MCF7 breast carcinoma cells and H1299 lung carcinoma cells were grown in RPMI-1640 medium supplemented with Figure 8 A schematic representation of a model for DDA3/EB3-mediated promotion of growth. APC2 has previously been shown to be a component of the b-catenin destruction complex, which binds microtubules and depletes cytoplasmic b-catenin by promoting its degradation (Nakagawa et al., 1998; van Es et al., 1999) . By interacting with each other and with APC2, DDA3 and EB3 may affect the dynamic formation of APC2/b-catenin destruction complex, resulting in the accumulation of cytoplasmic b-catenin, which in turn stimulates b-catenin-dependent transcription and growth promotion.
DDA3 interacts with EB3 and activates b-catenin signaling P-C Hsieh et al 10% fetal bovine serum (FBS). Mouse primary DM cells, kindly provided by Dr AC Chang (National Yang-Ming University, Taiwan), and HeLa human epithelial carcinoma cells were cultured in Dulbecco's modified Eagle's medium (DMEM), containing 10% FBS. The N2a mouse neuroblastoma cells were cultured in minimum essential medium with 10% FBS, 2 mM L-glutamine, 0.1 mM non-essential amino acids and 1 mM sodium pyruvate. TM4 mouse sertoli cells were grown in 1:1 mixture of Ham's F12 and DMEM medium supplemented with 5% horse serum and 2.5% FBS. All medium were supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin. Transfection was performed using LipofectAMINE PLUS reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.
Protein expression and antibody production Hexahistidine-tagged DDA3 and GST-tagged EB3 were expressed in an Escherichia coli system. The proteins were purified and immunized to rabbits for production of polyclonal antibodies against DDA3 or EB3, respectively.
GST pull-down assay
The cDNA fragments generated and the primers used in polymerase chain reaction (PCR) are summarized in Supplementary Table 1 . PCR fragments were ligated in-frame into pGEX-3X-KS (Amersham Biosciences, Piscataway, NJ, USA) and transformed to BL21, which were then grown in the presence of 0.1 mM isopropyl-b-D-thiogalactoside for 3 h at 301C. Cells were lysed by sonication in buffer A (50 mM TrisHCl, pH 7.4, 50 mM NaCl, 5 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 1% Triton X-100, 1 mM ethylenediaminetetraacetic acid (EDTA) and 15% glycerol), and the lysates were clarified by filtration through a 0.45 mM membrane. GST fusion proteins were purified by glutathione-Sepharose beads in buffer A. The [ 35 S]Met-labeled proteins were obtained using the TNT Quick Coupled Transcription/Translation system (Promega, Madison, WI, USA) according to the manufacturer's instructions. The GSTfusion proteins were immobilized on glutathione-Sepharose and incubated with [
35 S]Met-labeled proteins at 41C for 4 h. After washing with phosphate-buffered (PBS), the proteins were subjected to 10% SDS-PAGE for identification of interacting proteins.
Coimmunoprecipitation
Cells were transfected with 10 mg each of pFLAG-DDA3 and pHA-EB3 by LipofectAMINE PLUS reagent. After 24 h, cells were lysed in 100 ml of Triton X-100 extraction buffer (50 mM Tris-HCl, pH 7.4, 1% Triton X-100, 0.15 M NaCl, 10% glycerol, 5 mM NaF, 0.4 mM Na 3 VO 4 , 2 mM DTT and 1 mM PMSF) and incubated on ice for 30 min; the lysates were clarified by centrifugation at 14,000 g for 10 min at 41C. After pre-clearing with 30 ml protein A-Sepharose at 41C for 30 min, the lysates were incubated with 20 mg of anti-FLAG antibody (Sigma, St Louis, MO, USA), or anti-HA antibody (BAbCO, Richmond, CA, USA) adsorbed to protein A-Sepharose beads in NET buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM ethylene glycol bis(b-aminoethylether)-N,N,N 0 ,N 0 ,-tetraacetic acid) (EGTA), 5 mM MgCl 2 , 0.5% NP-40) at 41C for 16 h. The beads were washed extensively with NET buffer containing 1 mM PMSF, 2 mM DTT, 5 mM NaF, 0.4 mM Na 3 VO 4 , and boiled in SDS sample buffer for 10 min. After separating by 10% SDS-PAGE, the proteins were detected by Western blotting using specific antibodies.
Immunofluorescence analysis Cells were cultured on glass coverslips, fixed with 2% paraformaldehyde in PBS for 10 min, and permeabilized with 0.2% Triton X-100 in PBS for 5 min. The coverslips were incubated in PBS containing 10% BSA for 30 min and reacted with primary antibodies for 1 h at 371C, followed by reacting with appropriate secondary antibodies for 1 h at 371C. The mouse monoclonal antibody to a-tubulin (clone B-5-1-2) and anti-FLAG monoclonal antibody were from Sigma; the FITC-conjugated anti-mouse antibody, rhodamine-conjugated anti-mouse antibody and rhodamine-conjugated anti-rabbit antibody were from Jackson ImmunoResearch.
In vitro microtubule-binding assay Binding to microtubules was performed using the Spin-Down assay kit from Cytoskeleton. Microtubules (20 nM final concentration) were formed by mixing 20 ml of tubulin (5 mg/ ml) and 2 ml of taxol (200 mM) in General tubulin buffer (G-PEM) buffer (80 mM Pipes, pH 6.8, 1 mM MgCl 2 , 1 mM EGTA and 1 mM guanosine-5 0 -triphosphate). Appropriate amounts of GST-tagged proteins were incubated with 20 nM microtubules at 251C for 30 min, the microtubule-associated protein MAP2 and BSA were used as positive and negative controls, respectively. The mixture was layered on top of a cushion containing 400 g/l glycerol in G-PEM buffer in an ultracentrifuge tube. After centrifugation, the pellet was resuspended in sample buffer, and analysed by SDS-PAGE. GST-tagged proteins were detected by immunoblotting, and the control MAP2 and BSA, by Coomassie Blue staining.
In vitro tubulin polymerization assay Polymerization of tubulin was carried out according to the manufacturer's instructions using the fluorescence-based assay kit from Cytoskeleton. Polymerization was monitored by an increase in fluorescence emission at 420 over a period of 72 min at 371C, with excitation at 360 nm.
Luciferase reporter assay Cells were cotransfected with a suitable luciferase reporter plasmid in the presence of pRL-TK (Promega) and expression plasmids for DDA3 or EB3 as indicated using the LipofectA-MINE PLUS reagent. Cells were lysed and assayed after 24 h for luciferase activity using the dual-luciferase reporter assay system (Promega). The firefly luciferase activity obtained was normalized to that of Renilla.
RNA interference
The pSUPER-based strategy (Brummelkamp et al., 2002) was adopted to knockdown DDA3 and EB3 expression. For construction of pSUPER-DDA3 and pSUPER-EB3, two complementary 64 bp forward and reverse nucleotides containing 19 bp sense and antisense sequences (corresponding to nucleotides 101-119 of DDA3 and nucleotides 664-682 of EB3 gene) were synthesized, annealed and inserted into the BglII and HindIII sites of the pSUPER plasmid.
BrdU assay DNA synthesis was monitored by pulse-labeling the cells for 2 h with thymidine analog 5-bromo-2 0 -deoxyuridine (BrdU) (10 mM; Sigma). Cells were washed three times with PBS and fixed for 20 min at À201C in ethanol fixative (0.15 mM glycine in 70% EtOH, pH 2.0). After rehydration in PBS, BrdU incorporation was detected by reacting with an anti-BrdU monoclonal antibody (1:10; Roche Diagnostics Ltd, Rotkreuz, Switzerland) for 1 h at 371C, followed by rhodamine-conjugated anti-mouse antibody (1:500; Jackson ImmunoResearch), nucleus was stained with 4 0 -6-diamidino-2-phenylindole (DAPI) for 1 h. For quantitative analysis of immunofluorescence data, the proportion of BrdU-positive nuclei (BrdU labeling index) was assessed, based on a sample size of 500 cells per data point.
